摘要
目的探讨c-myc基因重排对弥漫大B细胞淋巴瘤（DLBCL）远期疗效的影响，为DLBCL预后判断提供循证医学依据。方法计算机检索中英文数据库，收集国内外公开发表的关于c-myc基因重排DLBCL的相关文献，采用RevMan5．2软件进行Meta分析。结果筛选文献，共有8篇纳入研究。Meta分析显示，c-myc重排阳性的DLBCL患者5年无进展生存和总生存较c-myc重排阴性患者差（HR=2．28，95％CI 1．64～3．18；lib=2．35，95％CI1．93～2．85）。结论c-myc基因重排是潜在的DLBCL预后不良的生物标志物。
Objective To investigate the significance of c-myc gene rearrangement on the long term efficacy of diffuse large B-cell lymphoma （DLBCL）, and to provide the evidence-based medicine for prognosis of DLBCL. Methods The Chinese and English database were searched to identify all the articles about the DLBCL with c-myc gene rearrangement by computer. Meta-analysis was completed by RevMan 5.2 software. Results A total of eight studies were included. The Meta-analysis results displayed that DLBCL patients with c-myc gene rearrangement had the poor prognosis. Five years progression free survival （PFS） and overall survival （OS） were significantly worse （FIR = 2.28, 95 % CI 1.64-3.18 and FIR = 2.35, 95 % CI 1.93-2.85）. Conclusion C-mye gene rearrangement is a potential biomarker for the poor prognosis of DLBCL.
出处
《白血病．淋巴瘤》
CAS
2016年第1期61-64,共4页
Journal of Leukemia & Lymphoma
基金
福建省医学创新课题（2012-cx-7）
